Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Harpoon Therapeutics Inc [HARP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 0.63%
SELL
20.00%
return 0.25%
Last Updated8 Mar 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

0.09% $ 23.01

BUY 154893 min ago

@ $22.46

Issued: 14 Feb 2024 @ 12:29

Return: 2.45%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -0.29 %

Live Chart Being Loaded With Signals

Commentary (8 Mar 2024 @ 16:00):

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States...

Stats
Today's Volume 6.40M
Average Volume 1.13M
Market Cap 865.08M
EPS $0 ( 2024-05-09 )
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -15.04
ATR14 $0.377 (1.64%)
Insider Trading
Date Person Action Amount type
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 395 783 Common Stock
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 10 000 8.000% Series A Redeemable Preferred Stock
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 299 430 Common Stock Warrant (Right to Buy)
2024-03-11 New Leaf Biopharma Opportunities Ii, L.p. Sell 85 750 Common Stock Warrant (Right to Buy)
2024-03-11 Silvernail Lauren P Sell 5 000 Common Stock
INSIDER POWER
75.98
Last 96 transactions
Buy: 30 137 007 | Sell: 5 308 481

Volume Correlation

Long: 0.48 (neutral)
Short: 0.40 (neutral)
Signal:(82.718) Neutral

Harpoon Therapeutics Inc Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Harpoon Therapeutics Inc Correlation - Currency/Commodity

The country flag 0.57
( weak )
The country flag 0.20
( neutral )
The country flag -0.65
( weak negative )
The country flag -0.79
( moderate negative )
The country flag -0.21
( neutral )
The country flag 0.80
( strong )

Harpoon Therapeutics Inc Financials

Annual 2022
Revenue: $31.92M
Gross Profit: $28.82M (90.30 %)
EPS: $-20.24
FY 2022
Revenue: $31.92M
Gross Profit: $28.82M (90.30 %)
EPS: $-20.24
FY 2021
Revenue: $23.65M
Gross Profit: $23.65M (100.00 %)
EPS: $-3.62
FY 2020
Revenue: $17.44M
Gross Profit: $17.44M (100.00 %)
EPS: $-1.990

Financial Reports:

No articles found.

Harpoon Therapeutics Inc Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 2.0024881362915 seconds
Number of API calls: 2
Number of DB calls: 8